Results 131 to 140 of about 216,694 (240)

Possible Contribution of Multiple Sclerosis Pathology to Treatment‐Resistant Schizophrenia: A Case Study

Neuropsychopharmacology Reports, Volume 46, Issue 3, September 2026.
A case of multiple sclerosis detected by brain MRI during evaluation for modified electroconvulsive therapy in the long‐term course of schizophrenia. This case discusses the clinical overlap between multiple sclerosis pathology and treatment‐resistant schizophrenia. ABSTRACT Multiple sclerosis (MS) can present with neurological and psychiatric symptoms
Sho Miura, Atsuko Nagaoka, Mizuki Hino, Risa Shishido, Masataka Hatano, Yuto Hosogai, Kazusa Miyahara, Yuta Oba, Kimihiko Kaneko, Yasuto Kunii, Hiroaki Tomita   +10 more
wiley   +1 more source

A Fast, Flexible Simulation Framework for Bayesian Adaptive Designs—The R Package BATSS

Pharmaceutical Statistics, Volume 25, Issue 5, September/October 2026.
ABSTRACT The use of Bayesian adaptive designs for randomised controlled trials has been hindered by the lack of software readily available to statisticians. We have developed a new software package (Bayesian Adaptive Trials Simulator Software—BATSS) for the statistical software R, which provides a flexible structure for the fast simulation of Bayesian ...
Dominique‐Laurent Couturier, Rainer Puhr, Stephane Heritier, Thomas Jaki, Elizabeth G. Ryan   +4 more
wiley   +1 more source

The Neurovascular Niche: A Gathering Venue for Neuroinflammation and Remyelination in Multiple Sclerosis

Acta Physiologica, Volume 242, Issue 9, September 2026.
ABSTRACT In the central nervous system (CNS), the tissue microenvironment is continuously monitored and regulated to secure the unobstructed function of neurons and of their networks. This is a key function of the neurovascular niche (NVN), which is the interface between the cells of the nervous tissue and the cells and the content of blood vessels. It
Ilias Kazanis, Maria Elena Silva, Alerie G. de la Fuente, Fernando de Castro, Francisco J. Rivera   +4 more
wiley   +1 more source

Targeting progressive multiple sclerosis: Toward mechanism‐informed precision medicine

Journal of Internal Medicine, Volume 300, Issue 3, Page 238-257, September 2026.
Abstract Multiple sclerosis has undergone a therapeutic revolution over the past three decades. Randomized clinical trials and real‐world data demonstrate that modern disease‐modifying therapies substantially reduce relapse rates and acute inflammatory activity detected by magnetic resonance imaging (MRI).
Fredrik Piehl, Gonçalo Castelo‐Branco, Maja Jagodic, Tomas Olsson   +3 more
wiley   +1 more source

Structure–Function Decoupling of the Sensorimotor and Default Mode Networks in Black Americans With MS

Annals of Clinical and Translational Neurology, Volume 13, Issue 8, Page 1558-1568, August 2026.
ABSTRACT Background and Objectives Multiple sclerosis (MS) exhibits racially disparate rates of disease progression. Black people with MS (B‐PwMS) experience a more severe disease course than non‐Hispanic White people with MS (NHW‐PwMS). Here we investigated structural and functional connectivity as well as structure–function decoupling in the ...
Emilio Cipriano, Giacomo Boffa, Maria Petracca, Marta Ponzano, Nicole Graziano, Claire Wigley, Claire Riley, Jonathan Howard, Pietro Bontempi, Sylvia Klineova, Fred Lublin, Matilde Inglese   +11 more
wiley   +1 more source

Impaired cerebrovascular reactivity is associated with disability and cognitive performance in relapsing-remitting multiple sclerosis. [PDF]

Neurol Sci
Ntais E, Kostadima V, Haski A, Tsamis K, Giannopoulos S, Konitsiotis S.   +5 more
europepmc   +1 more source

Normal‐Appearing White Matter Injury Mediates Chronic Deep Venous Hypoxia and Disease Progression in Multiple Sclerosis

Annals of Clinical and Translational Neurology, Volume 13, Issue 8, Page 1686-1696, August 2026.
ABSTRACT Objective To explore how cerebral hypoxia and Normal‐Appearing White Matter (NAWM) integrity affect MS lesion burden and clinical course. Methods Seventy‐nine MS patients, including 13 clinically isolated syndrome (CIS) patients and 66 relapsing–remitting multiple sclerosis (RRMS) patients, and 44 healthy controls (HCs) were recruited from ...
Xinli Wang, Huiying Wang, Zhizheng Zhuo, Ai Guo, Ke Lv, Decai Tian, Chao Chai, Yunyun Duan, Shuang Xia   +8 more
wiley   +1 more source

Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis. [PDF]

J Neurol Neurosurg Psychiatry
Kaçar S, van Nederpelt DR, Jelgerhuis JR, Coerver EME, Killestein J, Sormani MP, Ciccarelli O, Arnold DL, van Kempen ZLE, Uitdehaag BMJ, Barkhof F, Koch MW, Schoonheim MM, Eshaghi A, Strijbis EMM.   +14 more
europepmc   +1 more source

Anti‐CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

Annals of Clinical and Translational Neurology, Volume 13, Issue 8, Page 1697-1701, August 2026.
ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos, Marwa Al‐Dubai, Denise Walther, Dominic Borie, Jan D. Lünemann, Marc Pawlitzki, Sven G. Meuth, Solveig Henneicke, Stefan Vielhaber, Stefanie Schreiber   +9 more
wiley   +1 more source

Digital monitoring of disease activity in relapsing-remitting multiple sclerosis. [PDF]

J Neurol
Molenaar PCG, de Jong DJ, Hof SN, van Oirschot P, Bucur IG, Lam KH, Moraal B, Heskes TM, de Groot V, Uitdehaag BMJ, de Jong BA, Twisk JWR, Strijbis EMM, Killestein J.   +13 more
europepmc   +1 more source